Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Primary sclerosing cholangitis cuts survival in IBD patients

28 Sep 2020
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Patients with inflammatory bowel diseases (IBDs) suffer from higher mortality rates and are at an increased risk of cancer when they develop new-onset primary sclerosing cholangitis (PSC), a recent study has found.

Linking national medical and census databases in England, researchers identified 284,560 patients with incident IBD between April 2006 and 2016. Of these, 2,588 developed PSC. The primary goal of the study was to quantify the impact of new-onset PSC in IBD patients, across all subtypes, assessing its effect on disease outcomes and mortality.

The cumulative follow-up, until death or censor, was 1,994,441 person-years for those with IBD alone, and 18,823-person-years for IBD patients who developed PSC.

The onset of PSC worsened survival independently of sex, race, comorbidities, and ageing (time-dependent hazard ratio [HR], 3.20, 95 percent confidence interval [CI], 3.01–3.40; p<0.001).

Moreover, relative to the background population, the years of life lost following IBD diagnosis were 12.7 and 12.6 years in men and women with IBD alone. In comparators who developed PSC, the respective values were 17.1 and 16.4 years.

PSC onset also seemed to correlate with malignancies, with significantly elevated risk estimates for pancreatic cancer (time-dependent adjusted HR, 5.26, 95 percent CI, 2.81–9.84; p<0.001) and gallbladder cancer (adjusted HR, 9.19, 95 percent CI, 2.91–29.05). Another 164 PSC-IBD patients developed cholangiocarcinoma, while 47 had hepatocellular carcinoma. For all malignancies, advancing age at PSC diagnosis emerged as a significant risk factor.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.